ArticlePediatric research2026
Early diagnosis of serious bacterial infection in febrile infants using type I interferon signature.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFebrile infants ≤90 days are at high risk of serious bacterial infections, but prompt differentiation between viral and bacterial infections remains a challenge. Host gene expression signatures, particularly those involving the type I interferon (IFN) pathway, show promise as diagnostic tools. This study evaluates the ability of IFN signature to differentiate bacterial from viral infections in this population.
methodsThis is a prospective, single-center study. Infants ≤90 days were enrolled. All patients underwent complete blood count, CRP, PCT, and IFN signature, assessed by analyzing the expression of six interferon-stimulated genes. Based on routine investigations, patients were divided into bacterial (BI, n = 8) and non-bacterial infection (non-BI, n = 39) and healthy controls (HC, n = 3). Regression analysis was used to determine the variable's predictive correlation.
resultsForty-seven febrile infants were enrolled. IFN signature resulted significantly elevated in non-BI compared to BI (p < 0.001) and HC (p = 0.008), even within 12 h of fever onset. IFN demonstrated the highest AUC for predicting BI. Combining IFN with CRP or PCT yielded the most robust predictive models (AUC = 0.99 and 0.98).
conclusionsIFN signature resulted as a promising, reliable predictor of BI versus non-BI in febrile infants. This novel biomarker, combined with others, could improve the management of febrile infants reducing unnecessary antibiotics and hospitalizations. IMPACT: This is the first study to focus on the IFN signature in febrile infants under 90 days old, adding novel insights into the potential of host immune responses as diagnostic biomarkers. This study demonstrates that the peripheral blood interferon signature, specifically the expression of six IFN-stimulated genes, can distinguish bacterial from non-bacterial infections in febrile infants aged 90 days or younger in the very first hours of fever. The IFN score, when combined with traditional inflammatory markers, offers high sensitivity and specificity, making it a potential diagnostic tool for optimizing treatment and reducing unnecessary interventions.
Indexed as
Identifiers
40537537What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.